An overview of compassionate use programs in the european union member states

Intractable and Rare Diseases Research

Volumn 5, Issue 4, 2016, Pages 244-254

  Balasubramanian, Gayathri ^a   Morampudi, Suman ^a   Chhabra, Pankdeep ^a   Gowda, Arun ^a   Zomorodi, Behsad ^b  

^a FSRC   (India)

^b Phamax AG   (Switzerland)

Author keywords

Compassionate use; early access; European union; European union member states; orphan drugs; rare diseases; special access

Indexed keywords

COMPASSIONATE USE; DRUG INDUSTRY; EUROPEAN UNION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; LAW; REIMBURSEMENT; REVIEW; TREND STUDY;

EID: 85025076579     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.2016.01054     Document Type: Review

References (94)

1. Rahbari M, Rahbari NN. Compassionate use of medicinal products in Europe: Current status and perspectives. Bull World Health Organ. 2011; 89:163.
2. Patil S. Early access programs: Benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016; 7:4-8.
3. Global Genes. RARE Diseases: Facts and Statistics. https://globalgenes.org/rare-diseases-facts-statistics/ (accessed June 16, 2016).
4. Howes M. Compassionate use and the impact on clinical research. http://www.centerwatch.com/news-online/2016/04/11/compassionate-use-impact-clinical-research/ (accessed June 16, 2016).
5. Shire. Shire's Position on Offering Compassionate Use to Investigational Medicines. https://www.shire.com/who-we-are/how-we-operate/policies-and-positions/compassionate-use (accessed August 11, 2016).
6. Hyry HI, Manuel J, Cox TM, Roos JC. Compassionate use of orphan drugs. Orphanet J Rare Dis. 2015; 10:100.
7. Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics. 2009; 3:407-417.
8. European Medicines Agency. Compassionate use. http://www.ema.europa.eu/ema/index.jsp7curDpages/regulation/general/general_content_000293.jsp (accessed August 11, 2016).
9. European Medicines Agency. Guideline on Compassionate Use of Medicinal Products, Pursuant to Article 83 of Regulation (Ec) No 726/2004 European Medicines Agency. London, UK, 2007; pp. 1-8.
10. European Medicines Agency. Regulation (Ec) No 726/2004 of the European Parliament and of the Council of 31 March 2004.Agency EM, ed. European Medicines Agency, 2004; pp. 1-70.
11. Benisheva-Dimitrova DT. Challenges for the Pharmaceutical Legislative Implementation in Terms of an Accelerated Market Access After October 2005 University of Bonn, Bonn, 2006; pp. 1-68.
12. Urbinati D, Masetti L, Toumi M. Early Access Programmes (EAPs): Review of European system. In: ISPOR 15th Annual European Congress ISPOR, Berlin, 2012; p. 1.
13. Whitfield K, Huemer KH, Winter D, et al. Compassionate use of interventions: Results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials. 2010; 11:104.
14. EUCERD. Links to national authorities websites. http://www.eurordis.org/content/links-national-authorities-websites (accessed August 19, 2016).
15. European Commission. Inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products State of Play 2015. 2015; pp. 1-36.
16. FDA. Expanded Access (Compassionate Use). http://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm#main (accessed August 19, 2016).
17. U.S National Library of Medicine. FAQ: ClinicalTrials. govt - What is "Expanded Access". https://www.nlm.nih.gov/services/ctexpaccess.html (accessed August 19, 2016).
18. BioIndustry Association and Clinigen Group. Early access in practice BioIndustry Association and Clinigen Group, 2014; pp. 1-6.
19. Pharmalinx LLC P. Named Patient Programs. http://www.idispharma.com/sites/default/files/uploads/pharmavoice:epicept_may2010.pdf (accessed June 14, 2016).
20. Ceepharma. CEE countries give chance to drug pre-launch within Named Patient Programmes - Pharma & healthcare market in CEE & CIS - PMR http://www.ceepharma.com/news/103152/cee-countries-give-chance-to-drug-pre-launch-within-named-patient-programmes (accessed August 19, 2016).
21. European Medical Agency. Questions and answers on the compassionate use of medicines in the European Union European Medical Agency, 2010; pp. 1-3.
22. Agence nationale de sécurité du médicament et des produits de santé. Autorisations temporaires d'utilisation (ATU). http://ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-ATU/ATU-Reglementation/(offset)/8 (accessed August 12, 2016).
23. Bélorgey C. Temporary Authorisations for Use (ATU). http://agence-tst.ansm.sante.fr/html/pdf/5/atu_eng.pdf (accessed August 12, 2016).
24. Code de la Santé Publique. Legifrance: Article L5121-12. https://www.legifrance.gouv.fr/afichCodeArticle.do7cidT_exte=LEGITEXT000006072665&idArticle=LEGIARTI0_00006689900&dateTexte=&categorieLien=cid (accessed August 12, 2016).
25. Autorisation de mise sur le marché - Ministère des Affaires sociales et de la Santé. Temporary use authorizations (ATU). http://social-sante.gouv.fr/soins-et-maladies/medicaments/professionnels-de-sante/autorisation-de-mise-sur-le-marche/article/autorisations-temporaires-d-utilisation-atu (accessed August 12, 2016).
26. BfArM. "Compassionate use" programs. http://www.bfarm.de/EN/Drugs/licensing/clinicalTrials/compUse/_node.html (accessed August 12, 2016).
27. Agenzia Farmaco. Decreti, Delibere e Ordinanze Ministeriali. Agenzia Farmaco, 2003; pp. 1-2.
28. Agenzia Farmaco. Collection of national regulations about clinical trials with medicines. https://www.agenziafarmaco.gov.it/ricclin/it/node/3 (accessed August 12, 2016).
29. Aymé S, Rodwell C, eds. 2012 Report on the State of the Art oF Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases - Italy. EUCERD, 2012; pp. 1-20.
30. EURORDIS. Europlan - National Conferences Final Report of the Conference in Italy 2010; pp. 1-24.
31. Conference Bleue. Pricing and Reimbursement Questions. http://www.arthurcox.com/wp-content/uploads/2015/06/Pricing-and-Reimbursement-Questions.pdf (accessed August 12, 2016).
32. Hernández García C. Spanish routes for making available medicines to patients before authorisation. Spanish Agency of Medicines and Medical Devices (AEMPS); pp. 1-17.
33. Agencia Espan&tild;ola de Medicamentos y Productos Sanitarios. Instrucciones para la tramitación de solicitudes. http://www.aemps.gob.es/medicamentosUsoHumano/medSituacionesEspecialesAnstruccTramitacion.htm (accessed August 12, 2016).
34. State Agency. Boletín Oficial del Estado. 2009. http://www.boe.es/boe/dias/2009/07/20/pdfs/B0E-A-2009-12002.pdf (accessed August 12, 2016).
35. O'Connor D. Early Access to Medicines Scheme (EAMS). 2015; pp. 1-13.
36. Government of UK. The Human Medicines Regulations 2012 The Stationery Office, 2012; pp. 1-322.
37. Medicines and Healthcare Products Regulatory Agency. Apply for the early access to medicines scheme (EAMS). https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams (accessed August 12, 2016).
38. Government of UK. The supply of unlicensed medicinal products ("specials"). Norwich, 2014. http://www.legislation.gov.uk/uksi/2012/1916/pdfs/uksi_20121916_en.pdf (accessed August 12, 2016).
39. Austrian Federal Office for Safety in Health Care - BASG. Overview Compassionate Use Programs in Austria (AT). 2014. http://www.basg.gy.at/fUeadmin/redakteure/F_I453_Liste_CUP_in_AT_010.pdf (accessed August 12, 2016).
40. Austrian Federal Office for Safety in Health Care - BASG. Compassionate Use Programs in Austria. 2015.
41. Musch G. Unmet medical need strategy of FAMHP, moving to more adaptive pathways 2015; pp. 1-20.
42. FAMHP. 25 April 2014 - Royal Decree amending the Royal Decree of 14 December 2006 on human and veterinary medicines Federal Agency for Medicines and Health Products. http://www.fagg-afmps.be/en/humanuse/medicines/medicines/researchdevelopment/compassionateusemedicalneed (accessed August 19, 2016).
43. FAMHP. Compassionate use - medical need. www.fagg-afmps.be/en/human_use/medicines/medicines/research_development/compassionate_use_medical_need (accessed August 12, 2016).
44. Division de la Pharmacie et des Médicaments -Luxembourg. Division of Pharmacy and Medicines. www.sante.public.lu/fr/politique-sante/ministere-sante/direction-sante/div-pharmacie-medicaments/index.html (accessed August 12, 2016).
45. Geneesmiddelen CBG. Compassionate use programma. http://www.cbg-meb.nl/voor-mensen/voor-handelsvergunninghouders/inhoud/voor-aanvraag-handelsvergunning/compassionate-use-programma (accessed August 12, 2016).
46. Inspectie voor de Gezondheidszorg. Medicines without marketing authorization. http://www.igz.nl/english/medicines/medicines_without_marketing_authorization/ (accessed August 12, 2016).
47. Ravimiamet. The compassionate use programs under Estonian legislation. http://www.ravimiamet.ee/en/compassionate-use-programs-under-estonian-legislation (accessed August 12, 2016).
48. Danish Health and Medicines Authority. Danish Medicines Act Ministry of the Interior and Health. Danish Medicines Act Ministry of the Interior and Health, 2016; pp. 1-34.
49. Kavanagh C, Diamond D, O'Gorman M. http://www.arthurcox.com/wp-content/uploads/2014/01/European-Lawyer-Reference-2013-Guide-to-the-Distribution-and-Marketing-of-Drugs8478574_1.pdf. 2013. (accessed August 12, 2016).
50. HPRA. Access to Medicines Prior to Authorisation. www.hpra.ie/homepage/medicines/regulatory-information/medicines-authorisation/access-to-medicines-prior-to-authorisation (accessed August 12, 2016).
51. Lessem E. An Activist's Guide to Regulatory Issues: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment. TAG - Treatment Action Group, 2015; pp. 1-10.
52. Fimea. Special permission for compassionate use. http://www.fimea.fi/web/en/pharmaceutical_safety_and_information/special_permission_for_compassionate_use (accessed August 12, 2016).
53. Fimea. Special licence procedure in Finland. Finnish Medicines Agency - Fimea, 2014; pp. 1-3.
54. Logviss K, Krievins D, Purvina S. Rare diseases and orphan drugs: Latvian story. Orphanet J Rare Dis. 2014; 9:147.
55. State Agency of Medicines of the Republic of Latvia. Cabinet of Ministers Regulation No. 47, Procedure for Pharmacovigilance. https://www.zva.gov.lv/index.php.id=633&lang=&top=333&sa=380 (accessed August 19, 2016).
56. Lakemedelsverket/Medical Products Agency. Applications for medicinal products are made available for compassionate use (compassionate use program, CUP). https://lakemedelsverket.se/malgrupp/Foretag/Lakemedel/Compassionate-Use-Program/ (accessed August 16, 2016).
57. Riksdagen Parliment S. Drugs Act (1992: 859). http://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/lakemedelslag-1992859_sfs-1992-859 (accessed August 19, 2016).
58. Lakemedelsverkets forfattningssamling. Lakemedelsverkets forfattningssamling.Agency L-MP, ed. Lakemedelsverkets - Medical Products Agency, 2012; pp. 1-8.
59. The Ministry of Health and Social Welfare. Ordinance on Pharmacovigilance Welfare TMoHaS, ed. The Ministry of Health and Social Welfare, 2009; pp. 1-88.
60. Rodwell C, Aymé S eds., 2014 Report on the State of the Art of Rare Disease Activities in Europe - Croatia. EUCERD, 2014; pp. 1-11.
61. EUCERD. Greece Europlan national conference final report EUCERD, Athens 2012; pp. 1-33.
62. Eof. Information of Organization. http://www.eof.gr/web/guest (accessed August 19, 2016).
63. Medicines Working Group. Medicines with Special Legal Status. 2012. https://www.google.com/url.sa=t&rct=j&q=&esrc=s&source=web&cd=4&cad=rja&uact=8&ved=0ahUKEwi09L3r6szMAhXHRI4KHX7dDHQQFgguMAM&url=https%3A%2F%2Fhealth.gov.mt%2Fen%2Fsph%2FDocuments%2Fannex1_nsum.doc&usg=AFQjCNF6D_CTqdoCgZ6GIXUzYYzOzJioDnQ&bvm=bv.121421273,.c2E
64. Busuttil R. Guidelines for the supply of medicinal products for human use through processes which are not covered by the Medicines Act, 2003 and its subsidiary legislation (unlicensed medicinal products) - DH Circular 270/06 2006; pp. 1-7.
65. Rodwell C, Aymé S. 2014 report on the state of the art of rare disease activities in EUROPE - Malta. European Comission, 2014; pp. 1-10.
66. Leitao M, Teles G, Soares da Silva Associates Law Firm, R.L, Matoso F, Maia Cadete E. European lawyer reference series - Portugal. 2013; pp. 1-17.
67. EUCERD. Europlan national conference final report -Portugal Lisbon, 2016; pp. 1-58.
68. PISRS. Medicines Act (ZZdr-2). http://pisrs.si/Pis.web/pregledPredpisa.id=ZAKO6295 (accessed August 19, 2016).
69. State Institute for Drug Control. Act of 6 December 2007 on Pharmaceuticals and on Amendments to Some Related Acts (the Act on Pharmaceuticals) 2007. http://www.sukl.eu/uploads/Legislativa/Zakon_o_lecivech_EN_corr_clean2.pdf (accessed August 19, 2016).
70. State Institute for Drug Control. Use of non-authorized medicinal products. 2016. http://www.sukl.eu/medicines/use-of-non-authorised-medicinal-products.highlightWords=compassionate+use (accessed August 19, 2016).
71. Rodwell C, Aymé S, eds. 2014 Report on the State of the Art of Rare Disease Activities in Europe - Bulgaria. 2014; pp. 1-16.
72. Hasardzhiev S. Bulgarian national hepatitis plan and compassionate use regulations. http://www.elpa-info.org/elpa-news-reader/items/compassionate-use-in-hepatitis-c-saving-lives-of-patients-who-cannot-wait.htm.file=tl_files/elpa_downloads/2013%20content/ELPA%20Symposium%202013/Stanimir%20Hasardzhiev%20-%20 Bulgarian%20national%20hepatitis%20plan%20anc%20compassionate%20use%20regulations.ppt. Presentation presented at; 2016; Bulgaria.(accessed August 19, 2016).
73. EUCERD. Europlan national conference final report -Hungary. Budapest, 2013; pp. 1-36.
74. Lexology. European - pharmaceutical & healthcare newsletter. http://www.lexology.com/library/detail.aspx.g=d839298b-757c-4531-8b1d-4774fedd6472 (accessed August 19, 2016).
75. Jogtar. Act XCV of 2005 on Medicinal Products for Human Use and on the Amendment of Other Regulations Related to Medicinal Products. http://net.jogtar.hu/jr/gen/getdoc.cgi.docid=a0500095.tv&dbnum=62#lbj203id8e8 (accessed August 19, 2016).
76. Orszagos Gyôgyszerészeti és Élelmezés-egészségügyi. Laws. http://www.ogyei.gov.hu/laws_and_regulations/ (accessed August 19, 2016).
77. Aymé S, Rodwell C, eds. 2012 Report on the state of the art of rare disease activities in Europe of the European union committee of experts on rare diseases - Poland 2012; pp. 1-13.
78. Zakrzewski Palinka Sp. k. D MM, Kaczyn'ski T, Najbuk P. European lawyer reference series - Poland. 2016; pp. 1-16.
79. EUCERD. Europlan national conference final report -Romania Bucharest, 2013; pp. 1-36.
80. National Agency for Medicines and Medical Devices. Romania Newsletter - National Agency for Medicines and Medical Devices. National Agency for Medicines and Medical Devices, 2014. http://www.anm.ro/anmdm/en/_/INFORMATIVE%20BULLETIN/IB%203_2014.pdf (accessed August 19, 2016).
81. EUCERD. Slovakia europlan national conference final report EUCERD, Bratislava, 2013; pp. 1-46.
82. Partners Ca. Financial law news Cechova.sk, Bratislava, 2005; pp. 1-11.
83. Aymé S, Rodwell C, eds. 2013 Report on the state of the art of rare disease activities in Europe - Cyprus EUCERD, 2013; pp. 1-11.
84. Jones Day. Compassionate Use in Europe: A Patchy Framework for Early Market Entry. http://www.jonesday.com/compassionate-use-in-europe-a-patchy-frame-work-for-early-market-entry-08-20-2010/ (accessed August 19, 2016).
85. Degrassat-Theas A, Paubel P, Parent de Curzon O, Le Pen C, Sinegre M. Temporary authorization for use: Does the French patient access programme for unlicensed medicines impact market access after formal licensing. Pharmacoeconomics. 2013; 31:335-343.
86. PAREXEL. Managed Access Programs PAREXEL, 2015.
87. Bates A. Evidence of increased market share. Journal of Medical Marketing. 2008; 8:319-324.
88. PAREXEL. Expanded Access Programs. https://www.parexel.com/solutions/access/late-stage-clinical-operations/expanded-access-programs (accessed August 22, 2016).
89. McKinsey & Company. The secret of successful drug launches. http://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-secret-of-successful-drug-launches (accessed August 22, 2016).
90. Merck. Access to Investigational Medicines. http://www.merck.com/about/views-and-positions/access-to-medicines/home.html (accessed August 22, 2016).
91. Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015; 372:279-286.
92. Plate V. The Impact of Off-Label, Compassionate and Unlicensed Use on Health Care Laws in preselected Countries. Deutsche Gesellschaft fur Regulatory Affairs, Bonn, 2009; pp. 1-174.
93. European Medicines Agency. Human regulatory -Adaptive pathways. http://www.ema.europa.eu/ema/index.jsp.curl=pages/regulation/general/general_content_000601.jsp (accessed August 22, 2016).
94. European Medicines Agency. Human Regulatory -Adaptive Pathways. http://www.ema.europa.eu/ema/index.jsp.curl=pages/regulation/general/general_content_000601.jsp&mid=WC0b01ac05807d58ce (accessed August 22, 2016).